According to our hypothesis, measuring CYFRA 21-1 and the tyrosine kinase human epidermal growth factor receptor 2 (EGFR2) should allow identifying breast cancer with positive and negative HER2 expression [14]. This evidence concerns the gene ERBB2 and breast cancer.